Male breast cancer remains understudied despite evidence of rising incidence. Using a co-
ordinated multi-centre approach, we present the first large scale biomarker study to define …

Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and
assessed clinicopathological information, together with data from 15 published studies …

Introduction Male breast cancer accounts for around 1% of all breast cancer cases but the
incidence has risen in recent years. This study aimed to classify the molecular subtypes of …

Objective. To determine if male breast carcinogenesis was similar to its more common
female counterpart, we compared incidence patterns among men and women with breast …

Male breast cancer (MBC) is a poorly characterized disease because of its rarity. Clinical
management is based on results obtained from randomized trials conducted in women …

Purpose: Male breast cancer is rare, and its genomic landscape has yet to be fully
characterized. Lacking studies in men, treatment of males with breast cancer is extrapolated …

Important differences have begun to emerge concerning the molecular profile of female and
male breast cancer which may prove to be of therapeutic value. This review examined all the …

Background. Male breast cancer (MBC) is an uncommon disease and there is limited
information on the prognostic impact of routinely used clinicopathological parameters …

Purpose Male breast cancer is an uncommon disease, and population-based information
regarding prognostic factors is limited. Most cases are hormone receptor (HR) positive; …

549 Background: Because male breast cancer (BC) is rare, there is little known about the
disease and treatment is extrapolated from female BC. Newer molecular technologies have …